Indian equities are poised for a constructive phase, with strategists anticipating earnings acceleration and a potential revival in foreign investor interest. While near-term earnings surprises are limited, FY27 is projected to see significant growth. Pharma is favored over IT, with selective opportunities in midcaps and other sectors.
Positive Breakout: These 5 stocks cross above their 200 DMAs
In the NSE list of stocks with a market cap over Rs 10,000 crore five stocks’ closing prices crossed above their 200-day moving averages (DMA)